Delving into the Latest Updates on Buprenorphine with Synapse

Overview

Basic Info

Drug Type

Small molecule drug

Synonyms

NanoBUP, Oral long-acting extended-release buprenorphine(Lyndra Therapeutics), 丁丙诺菲

+ [11]

Target

κ opioid receptor x μ opioid receptor

Action

agonists, antagonists

Mechanism

κ opioid receptor agonists(Kappa opioid receptor agonists), μ opioid receptor antagonists(Mu opioid receptor antagonists)

Therapeutic Areas

Nervous System DiseasesOther Diseases

Active Indication

Inactive Indication

AnalgesiaCancer PainIntervertebral Disc Disease+ [9]

Originator Organization

OrphoMed, Inc.

Active Organization

Purdue Pharma LP

Camurus ABIntelGenx Corp.

+ [7]

Inactive Organization

BioDelivery Sciences International, Inc.

Titan Pharmaceuticals, Inc.

Grünenthal GmbH

+ [3]

License Organization

Camurus AB

Titan Pharmaceuticals, Inc.Indivior PLC

+ [4]

Drug Highest PhaseApproved

First Approval Date

United States (30 Jun 2010),

Chronic Pain

RegulationPriority Review (United States), Fast Track (United States), Orphan Drug (United States)

Login to view timeline

Structure/Sequence

Molecular FormulaC29H41NO4

InChIKeyRMRJXGBAOAMLHD-IHFGGWKQSA-N

CAS Registry52485-79-7

The investigators plan to conduct an R61/33 hybrid type 2 implementation-effectiveness trial that includes 1) a one-year exploratory R61 phase that will enable the development of the intervention protocol needed for the R33 trial phase including concrete R61 phase milestones; 2) a four-year R33 phase that will include a concurrent implementation evaluation and a randomized control trial.

Start Date01 Nov 2025

Sponsor / Collaborator

Duke University

[+4]

NCT05339256

/ Not yet recruitingPhase 2IIT

A Randomized, Controlled Trial of Sublingual Buprenorphine Through Telemedicine vs In-Person Care as Usual in the Treatment of Opioid Use Disorder

This study will compare in-person induction and maintenance dosing of sublingual buprenorphine to induction and maintenance dosing of sublingual buprenorphine through comprehensive telehealth sessions and telehealth medication for opioid use disorder (MOUD).

Start Date01 Oct 2025

Sponsor / Collaborator

The New York State Psychiatric Institute

[+1]

NCT06441604

/ Not yet recruitingPhase 2IIT

Extended-release Buprenorphine as a Novel Low-dose Induction Strategy

This is a clinical trial to characterize the safety and pharmacokinetics of using extended-release buprenorphine (XR-BUP) as a novel low-dose buprenorphine induction strategy. Individuals with a diagnosis of Opioid Use Disorder (OUD) (n=30) will be admitted to an inpatient unit to complete study procedures over the course of 3 days. Participants will receive fentanyl to prevent the emergence of withdrawal. Each participant will then receive a single injection of XR-BUP after which study staff will monitor for any precipitated withdrawal.

Start Date01 Aug 2025

Sponsor / Collaborator

The Brigham & Women's Hospital, Inc.

[+1]

100 Clinical Results associated with Buprenorphine

Login to view more data

100 Translational Medicine associated with Buprenorphine

Login to view more data

100 Patents (Medical) associated with Buprenorphine

Login to view more data

11,812

Literatures (Medical) associated with Buprenorphine

31 Dec 2025·ANNALS OF MEDICINE

Mindful moms: acceptability and impact of co-designed and digitally delivered video meditations for pregnant and parenting women with opioid use disorder

Article

Author: Lord, Sarah E. ; Rao, Deepika

INTRODUCTION:

Perinatal opioid use disorder (OUD) remains a public health epidemic. Stress, anxiety and depression are disproportionately high among this population and are associated with poor recovery outcomes. Mindfulness interventions show promise for supporting recovery for women. This paper reports results of a pilot study to evaluate initial efficacy and acceptability of digitally delivered mindfulness meditation videos to reduce stress and promote mindfulness among women in recovery.

METHODS:

Women with lived experience of OUD were recruited from three outpatient programs that provided care to pregnant and parenting women with a history of opioid use in rural northern New England (2 maternity care settings that offered buprenorphine as part of their service menu and 1 academic substance use treatment setting). In a pre-post study design, participants were randomly assigned to receive four of 16 short meditation videos, each delivered by email in a survey link over a 2-week period (2 per week) Videos were co-designed in earlier work with representative end-users, guided by evidence-based mindfulness interventions. Assessment included the Perceived Stress Scale and the Mindfulness Attention Awareness Scale. Participants rated each video on usefulness, enjoyability, ability to lower anxiety, and intention to use in the future. Participants also provided open-ended feedback about the videos. Data were analyzed using descriptive statistics, paired t-tests, and generalized linear modeling.

RESULTS:

A total of 20 women, ages 24-36 years, completed the pilot study. Most participants (95%) were white and non-Hispanic, reflecting the rural region. Marginal mean perceived stress scores decreased significantly from 21.49 to 19.85 [p = 0.05, d = 0.43] and mean mindfulness scores increased significantly from 3.47 to 3.76 [p = 0.04, d = 0.45]. Overall, the meditation videos were rated as highly acceptable and useful and a majority (80%) indicated intention to use the meditations in the future.

CONCLUSION:

Digitally delivered meditation videos were highly acceptable and useful to participants and the low dose intervention reduced stress and improved mindfulness. Findings inform directions for future research with larger samples to evaluate the effectiveness of this accessible digital intervention to support women in recovery and strategies for broadly implementing the intervention.

01 Oct 2025·COMPARATIVE BIOCHEMISTRY AND PHYSIOLOGY C-TOXICOLOGY & PHARMACOLOGY

Effects of re-enter water on antioxidant, immune, intestinal flora and metabolome of Chinese mitten crab (Eriocheir sinensis) after high temperature air exposure

Article

Author: Wang, Shihui ; Luo, Liang ; Yang, Yuhong ; Li, Zhiqiang ; Zhao, Zhigang ; Guo, Kun ; Deng, Xiangyi ; Zhang, Rui

Both air exposure stress and heat stress can cause stress responses of Eriocheir sinensis and affect its normal life activities. The objective of this research was to investigate the impact of re-enter water treatment on immunoenzyme activity, immune-related gene expression, hemolymph parameters, intestinal microbiota composition, and metabolomic profiles in Eriocheir sinensis after being subjected to high-temperature air exposure. The findings indicated that the re-enter water effectively mitigated the negative impacts of high-temperature air exposure on both antioxidant and immune capacities. Following treatment with high-temperature air, levels of acid phosphatase (ACP), alkaline phosphatase (AKP), aspartate aminotransferase (AST), and alanine aminotransferase (ALT) were significantly elevated compared to their baseline values (P < 0.05), followed by a decline as re-enter water started with recovery to baseline levels detected at 24 h after re-enter water. Additionally, the levels of heat shock proteins HSP90 and HSP70 exhibited a notable rise after being subjected to high-temperature air. Nevertheless, after 24 h of soaking treatment, these levels reverted to values similar to those recorded initially. However, after re-enter water treatment, the changes in intestinal microbial composition and metabolic level caused by high temperature air exposure were not effectively improved. The analysis of intestinal microbiota revealed that the relative abundance of Bacteroidetes in the recovery group was significantly lower compared to the initial group, whereas the relative abundances of Proteobacteria and Firmicutes were found to be higher than those in the initial group. Concurrently, metabolomics analysis indicated a significant increase in palmitic acid metabolism levels within the high-temperature air group (P < 0.05), while glycine content showed a notable decrease (P < 0.05), and the metabolic changes caused by high temperature air exposure was still not fully recovered after re-enter water.

01 Sep 2025·Journal of substance use and addiction treatment

Association between buprenorphine adherence for opioid use disorder and clinical events and healthcare spending among older patients

Article

Author: Thornton, J Douglas ; Olateju, Olajumoke A ; Shrestha, Mina

BACKGROUND:

Buprenorphine adherence in older adults with opioid use disorder (OUD) remains underexplored. This study investigated the associations between buprenorphine adherence and risks of opioid overdose, hospitalization, and healthcare spending among older adults to help inform practice and policy.

METHODS:

In this retrospective cohort study, we utilized the Merative MarketScan® Database (2017-2019) to identify Medicare Advantage enrollees with OUD who initiated buprenorphine and were retrospectively followed for 180 days. We classified patients as adherent (Proportion of Days Covered ≥0.80) or non-adherent to buprenorphine. We balanced baseline characteristics between groups using an inverse probability treatment weighting approach. We then evaluated the associations between adherence and the risks of opioid overdose and all-cause hospitalization using discrete-time survival and Cox proportional hazards models respectively. Finally, we estimated differences in healthcare spending between adherent and non-adherent patients using generalized linear models.

RESULTS:

The cohort included 631 patients (379 [60 %] male; mean (SD) age:67 [2.8] years). Among them, 437 (69 %) were adherent to buprenorphine. Patients with a history of chronic pain, mental health disorders, and diabetes were less likely to adhere while higher average daily doses of buprenorphine were associated with increased adherence. Adherence was associated with reduced risks of opioid overdose (HR:0.76; 95%CI:0.59-0.93) and hospitalization (HR:0.55; 95%CI:0.42-0.73). Healthcare spending among adherent patients was $40,200 [95%CI:$54,712-25,687]) lower than in non-adherent patients. These findings were consistent across robustness and sensitivity analyses.

CONCLUSIONS:

Buprenorphine adherence was associated with reduced risks of opioid overdose, hospitalization, and healthcare spending in the overall population of older individuals with OUD. Enhancing adherence to buprenorphine should be prioritized in OUD treatment strategies among this population.

76

News (Medical) associated with Buprenorphine

18 Jul 2025

·www.einpresswire.com

New Opioid Use Disorder Treatment Hub Now Open in Bennington

For Immediate Release: July 18, 2025 Media Contact: Kyle Casteel - Media Lead Communication Office │ Department of Health 802-863-7280 │ [email protected] New Opioid Use Disorder Treatment Hub Now Open in Bennington Grand opening event planned for July 23 WATERBURY, VT — A new treatment hub for opioid use disorder is now open in Bennington, marking a significant expansion to the state's network of services for people recovering from substance misuse. The site is operated by BayMark Health Services – known as BAART Programs in Vermont – which is North America’s largest provider of medication-assisted treatment for substance use disorders. BAART Bennington began providing services in June and will celebrate a grand opening on July 23. “The opening of this facility is a testament to years of hard work and collaboration between the Health Department, BayMark, the Bennington community and many more partners,” said Health Department Deputy Commissioner Kelly Dougherty, who oversees the state’s substance use treatment programs. “By adding this new hub in Bennington to our statewide system of care, we are improving access and reducing barriers for Vermonters in recovery.” Vermont’s hub-and-spoke opioid treatment service system is organized through geographic regions—Northwest, Northeast, Central, Southeast, and Southwest. With the opening of BAART Bennington, each region now has at least one “hub,” a licensed Opioid Treatment Program with the authority to dispense buprenorphine and methadone, two powerful medications used to treat individuals with opioid use disorder. “Spokes” are healthcare practices that can provide office-based treatment supported with buprenorphine – previously the only level of care available in Bennington. “Before the Bennington hub opened, people seeking this level of treatment needed to travel significant distances, or outside of the state, to receive care,” Dougherty said. “Opioid misuse continues to impact our communities. Having accessible treatment for people in Vermont remains crucial.” The Health Department is supporting the new hub in Bennington with a $3.9 million grant to help cover startup, operational costs, and the cost of treatment for those without insurance through July 2026. BAART Bennington has an estimated capacity to serve about 400 people in need of medication to treat opioid use disorder annually, and offers other recovery services including case management, addiction and relapse prevention education, and referrals to community resources. Health officials said over 11,000 people received opioid treatment services from Vermont’s hub-and-spoke system of care in 2023. Grand Opening: Media are invited to BAART Bennington’s official grand opening at 120 Depot St, Ste 4 Bennington, VT 05201. The event is scheduled July 23 from 4 p.m. to 6 p.m. A ribbon-cutting ceremony will be followed by tours of the facility. Please RSVP with Sean Cossey at [email protected] by July 22. # # # About the Department of Health We have been the state's public health agency for more than 130 years, working every day to protect and promote the health of Vermonters. Visit HealthVermont.gov ─ Join us @HealthVermont on Facebook , Instagram , YouTube Translated Information – Print, video and audio resources are translated into many of the languages used in Vermont. Visit HealthVermont.gov/Translations for searchable tables of documents in each of the nine languages – including about preventing illness, healthy homes, and staying safe and healthy during extreme events like storms, power outages, hurricanes, and flooding. Legal Disclaimer: EIN Presswire provides this news content "as is" without warranty of any kind. We do not accept any responsibility or liability for the accuracy, content, images, videos, licenses, completeness, legality, or reliability of the information contained in this article. If you have any complaints or copyright issues related to this article, kindly contact the author above.

10 Jul 2025

·www.fiercebiotech.com

Eolas regains opioid use disorder drug abandoned by AstraZeneca

The California-based biotech said it has secured the full development rights to the asset.\n AstraZeneca may have washed its hands of AZD4041 after the opioid use disorder (OUD) prospect demonstrated a potential drug-drug interaction last year, but the pharma’s development partner, Eolas Therapeutics, isn’t ready to give up.AstraZeneca ended work on the orexin 1 receptor antagonist in November 2024 after a phase 2 study identified a “potential drug-drug interaction” with the widely used antifungal itraconazole. But Eolas—which was co-developing AZD4041 with AstraZeneca—announced this morning that it has taken ownership of the molecule.The California-based biotech said it has secured the full development rights to the asset, with plans to take the therapy into a fresh phase 2 trial.“We are grateful to AstraZeneca for their collaboration and confidence in our ability to lead this program forward,” Eolas CEO Albert Man said in a July 10 release. “AZD4041 demonstrated promising preclinical data on addictive behaviors and has completed phase 1 studies.”“Clinically significant drug-drug interactions are not anticipated within the range of doses which Eolas will test for efficacy,” Man added. “This compound represents a unique opportunity to develop a non-opioid therapeutic that we believe could significantly improve outcomes for people living with opioid dependence and other addictions.” U.S. health officials have been seeking out fresh ways to combat the opioid epidemic. Buprenorphine—an old medicine used to treat pain and opioid dependence—was approved to treat OUD in 2023 in the form of Braeburn’s Brixadi.Eolas first began working with AstraZeneca on AZD4041 in 2015 as part of a deal worth up to $145 million in biobucks. The initial plan was to assess the therapy program for smoking cessation as well as other indications.The biotech didn’t share the financial details of the latest handover of rights for AZD4041 this morning.

Phase 1Phase 2Drug Approval

30 Jun 2025

·www.prnewswire.com

Indivior Announces Inclusion in the U.S. Russell 2000® and 3000® Indexes

RICHMOND, Va., June 30, 2025 /PRNewswire/ -- Indivior PLC (Nasdaq / LSE: INDV) will be added as a member of the U.S. small-cap Russell 2000® Index, effective after the U.S. market opens today as part of the 2025 Russell indexes reconstitution. The annual reconstitution of the Russell U.S. indexes captures the 4,000 largest U.S. stocks as of April 30, ranking them by total market capitalization. Membership in the Russell 2000® Index, which remains in place for one year, is based on membership in the broad-market Russell 3000® Index. The stock also was automatically added to the appropriate growth and value indexes. "Indivior's inclusion in the U.S. Russell indexes further aligns our capital markets presence with our growing U.S. business profile. In 2024, 85% of our net revenue was generated in the U.S. predominately from SUBLOCADE®, our first-in-class, long-acting injectable medication for the treatment of opioid use disorder. We are committed to building our U.S. presence and increasing value for our stakeholders," said Joe Ciaffoni, Chief Executive Officer of Indivior. Russell indexes are widely used by investment managers and institutional investors for index funds and as benchmarks for active investment strategies. According to data as of the end of June 2024, about $10.6 trillion in assets are benchmarked against the U.S. Russell indexes, which belong to FTSE Russell, the global index provider. For more information on the Russell 2000® and 3000® indexes and the Russell indexes reconstitution, go to the "Russell Reconstitution" section on the FTSE Russell website. About Indivior: Indivior is a global pharmaceutical company working to help change patients' lives by developing medicines to treat opioid use disorder (OUD). Our vision is that all patients around the world will have access to evidence-based treatment for OUD and we are dedicated to transforming OUD from a global human crisis to a recognized and treated chronic disease. Building on its global portfolio of OUD treatments, Indivior has a pipeline of product candidates designed to expand on its heritage in this category. Headquartered in the United States in Richmond, VA, Indivior employs over 1,000 individuals globally and its portfolio of products is available in over 30 countries worldwide. Visit  to learn more. Connect with Indivior on LinkedIn by visiting . About FTSE Russell : FTSE Russell is a global index leader that provides innovative benchmarking, analytics and data solutions for investors worldwide. FTSE Russell calculates thousands of indexes that measure and benchmark markets and asset classes in more than 70 countries, covering 98% of the investable market globally. FTSE Russell index expertise and products are used extensively by institutional and retail investors globally. Approximately $18.1 trillion is benchmarked to FTSE Russell indexes. Leading asset owners, asset managers, ETF providers and investment banks choose FTSE Russell indexes to benchmark their investment performance and create ETFs, structured products and index-based derivatives. A core set of universal principles guides FTSE Russell index design and management: a transparent rules-based methodology is informed by independent committees of leading market participants. FTSE Russell is focused on applying the highest industry standards in index design and governance and embraces the IOSCO Principles. FTSE Russell is also focused on index innovation and customer partnerships as it seeks to enhance the breadth, depth and reach of its offering. FTSE Russell is wholly owned by London Stock Exchange Group. For more information, visit FTSE Russell. SOURCE Indivior PLC WANT YOUR COMPANY'S NEWS FEATURED ON PRNEWSWIRE.COM? 440k+ Newsrooms & Influencers 9k+ Digital Media Outlets 270k+ Journalists Opted In GET STARTED

100 Deals associated with Buprenorphine

Login to view more data

External Link

KEGG	Wiki	ATC	Drug Bank
D07132	Buprenorphine	N07BC01	DB00921

R&D Status

Approved

10 top approved records.

Login

to view more data

Indication	Country/Location	Organization	Date
Opioid-Related Disorders	United States	Braeburn, Inc.	23 May 2023
Opium Dependence	European Union	Camurus AB	20 Nov 2018
Opium Dependence	Iceland	Camurus AB	20 Nov 2018
Opium Dependence	Liechtenstein	Camurus AB	20 Nov 2018
Opium Dependence	Norway	Camurus AB	20 Nov 2018
Opioid abuse	United States	Indivior, Inc.	30 Nov 2017
Pain	United States	Purdue Pharma LP	13 Oct 2017
Chronic Pain	United States	Purdue Pharma LP	30 Jun 2010

Developing

10 top R&D records.

Login

to view more data

Indication	Highest Phase	Country/Location	Organization	Date
Cancer Pain	Phase 3	China	LTS LOHMANN Therapie-Systeme AG	10 Jun 2019
Cancer Pain	Phase 3	China	Beijing Mengdi Pharmaceutical Co. Ltd.	10 Jun 2019
Cancer Pain	Phase 3	China	Grünenthal GmbH	10 Jun 2019
Analgesia	Phase 3	-	Purdue Pharma LP	01 Nov 2011
Pain, Postoperative	Phase 3	-	Purdue Pharma LP	01 Nov 2011
Intervertebral Disc Disease	Phase 3	China	Beijing Mengdi Pharmaceutical Co. Ltd.	01 Aug 2009
Musculoskeletal Pain	Phase 3	China	Beijing Mengdi Pharmaceutical Co. Ltd.	01 Aug 2009
opioid dependence methadone	Phase 3	United States	Titan Pharmaceuticals, Inc.	01 Sep 2008
Osteoarthritis, Spine	Phase 3	United States	Purdue Pharma LP	01 Apr 2004
Osteoarthritis, Knee	Phase 3	United States	Purdue Pharma LP	01 Jun 1999

Login to view more data

Clinical Result

Indication

Phase

Evaluation

View All Results

Study	Phase	Population	Analyzed Enrollment	Group	Results	Evaluation	Publication Date


NCT02651584 (PRNewswire) Manual	Phase 3	Opioid-Related Disorders	123	BRIXADI (fentanyl-positive)	ssjhygpipk(ewmrsshunu) = ikbzezxcvg gtqmevfreo (foormugupa ) View more	Positive	25 Jun 2024
				buprenorphine + naloxone (fentanyl-positive)	ssjhygpipk(ewmrsshunu) = zndvrmexoe gtqmevfreo (foormugupa ) View more
NCT02651584 (Pubmed)	Phase 3	fentanyl-positive \| norfentanyl	428	Subcutaneous Buprenorphine	knwckalsbi(aphrkfsnjd) = gisivvrskx ieccwyozlp (uwidcvbbvf )	Positive	03 Jun 2024
				Sublingual Buprenorphine-Naloxone	knwckalsbi(aphrkfsnjd) = sptoiwodzp ieccwyozlp (uwidcvbbvf )
NCT02611752 (FDA) Manual	Phase 2	Opioid-Related Disorders	47	BRIXADI	nyukzcepzu(qrdooulhaq) = No active intramuscular hydromorphone dose resulted in a mean drug liking VAS Emax score of 11 mm or greater when compared to placebo wehxxhgyab (fqocdtryvs )	Positive	23 May 2023
				Placebo
NCT02651584 (FDA) Manual	Phase 3	Opioid-Related Disorders	428	BRIXADI	tmhfckzncz(ohbtwrehei) = gyotmmxqpg vxaaftxhpj (lhsipihyhb ) View more	Positive	23 May 2023
				buprenorphine/naloxone	tmhfckzncz(ohbtwrehei) = mpphlgzdrg vxaaftxhpj (lhsipihyhb ) View more
NCT03818399 (VOTIVE, CTgov)	Phase 3	Opiate Overdose \| Opioid abuse	19	SUBLOCADE	fybzoyuzbj = fmpllsdmeo lyvxvlmafg (lteghbskeh, hihmzrfuyn - kvelefsddd) View more	-	05 May 2022
NCT03604159 (CTgov)	Phase 4	Opium Dependence	52	Buprenorphine Extended Release (Buprenorphine Extended-Release)	cvqehszhtw = vmqbjggolp kjrrrsglzn (ulcsfsagqz, xnyqlmpfzs - ushwzqpmzu) View more	-	11 Jan 2022
				Buprenorphine+Zubsolv (Sublingual Buprenorphine)	cvqehszhtw = acftyrudjz kjrrrsglzn (ulcsfsagqz, dtllkskxre - ixadzvlhdr) View more
NCT02891798 (CTgov)	Phase 3	Pain	98	Bupivacaine	hwrmoteili(vbeucgkteq) = dyimqfzted myvxhrarng (ohiqpzswnj, 2.38) View more	-	20 Dec 2021
NCT02891798 (Pubmed \| Pain Med)	Phase 3	-	98	BPV-BCD	dkwdxfhdbn(eimpyyucfo) = zykawfhypu gscscspmkl (doxbceptep, 0.6 - 3.0)	-	03 Nov 2021
NCT01402492 (CURB, CTgov)	Phase 2/3	Cocaine-Related Disorders	302	Naltrexone+Buprenorphine (BUP4+XR-NTX)	bishxzrgcg(wlxtdlzzlw) = ftariabqxp qdliujkyrg (jmhyzbwzzy, 5.25) View more	-	29 Oct 2021
				Naltrexone+Buprenorphine (BUP16+XR-NTX)	bishxzrgcg(wlxtdlzzlw) = owxwzihgyu qdliujkyrg (jmhyzbwzzy, 6.77) View more
NCT03861338 (CTgov)	Phase 1/2	Opioid-Related Disorders \| Opioid abuse	11	Sublocade	vpwzhddybu = refxdjnwcs qreejuckbh (nuhaybdbev, wjjthybkhu - kymncvlbyb) View more	-	09 Mar 2021